SCHEMBL465332

SCHEMBL465332

OCCCN(CCCO)Cc1ccccc1

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ACKR3 P25106 1/20 0.52
HDAC3 O15379 2/20 0.50
HDAC1 Q13547 2/20 0.50
HDAC2 Q92769 2/20 0.50
HDAC8 Q9BY41 2/20 0.50
NCOR2 Q9Y618 2/20 0.50
HTT P42858 2/20 0.50
OPRM1 P35372 2/20 0.49
OPRD1 P41143 2/20 0.49
OPRK1 P41145 2/20 0.49
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
HSD17B10 Q99714 2/20 0.45
KDM4E B2RXH2 1/20 0.45
ALDH1A1 P00352 1/20 0.45
LMNA P02545 1/20 0.45
TDP1 Q9NUW8 1/20 0.44
TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22783695 0.98 ACKR3 (0.51) ACKR3HDAC3HDAC1HDAC2HDAC8
SCHEMBL10420078 0.96 HDAC3 (0.54) ACKR3HDAC3HDAC1HDAC2HDAC8
SCHEMBL10419027 0.96 HDAC3 (0.54) ACKR3HDAC3HDAC1HDAC2HDAC8
SCHEMBL14968252 0.96 HTT (0.56) ACKR3HDAC3HDAC1HDAC2HDAC8
SCHEMBL140525 0.96 HDAC3 (0.54) ACKR3HDAC3HDAC1HDAC2HDAC8
SCHEMBL11683525 0.92 HDAC3 (0.54) ACKR3HDAC3HDAC1HDAC2HDAC8
SCHEMBL10420504 0.92 HDAC3 (0.54) ACKR3HDAC3HDAC1HDAC2HDAC8
SCHEMBL8993117 0.92 HDAC3 (0.54) ACKR3HDAC3HDAC1HDAC2HDAC8
SCHEMBL3752310 0.89 HDAC3 (0.57) ACKR3HDAC3HDAC1HDAC2HDAC8
Hydrochloric Acid SCHEMBL31687512 0.89 HTT (0.46) ACKR3HDAC3HDAC1HDAC2HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12600711-B2 Triazacyclododecansulfonamide (TCD)-based protein secretion inhibitors KEZAR LIFE SCIENCES, INC. (US) 2026-04-14 US disclosed
CN-118355096-A Water-soluble metal processing oil 出光兴产株式会社 2024-07-16 CN disclosed
CN-113603683-B Substituted phenyl oxazolidinones for antimicrobial treatment 结核病药物开发全球联盟公司 2024-06-14 CN disclosed
CN-112262129-B Triazacyclododecanesulfonamide (\"TCD\") based protein secretion inhibitors 科智生命科学公司 2024-05-14 CN disclosed
US-11964949-B2 Substituted phenyloxazolidinones for antimicrobial therapy THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) 2024-04-23 US disclosed
US-20230357663-A1 WATER-SOLUBLE METALWORKING FLUID IDEMITSU KOSAN CO.,LTD. (JP) 2023-11-09 US disclosed
US-20230348810-A1 WATER-SOLUBLE METALWORKING FLUID IDEMITSU KOSAN CO.,LTD. (JP) 2023-11-02 US disclosed
WO-2023162707-A1 WATER-SOLUBLE LUBRICANT 出光興産株式会社 2023-08-31 WO disclosed
EP-3765447-B1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2023-07-12 EP disclosed
EP-3765447-B1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2023-07-12 EP disclosed
US-20110021687-A1 POLYAMIDE NANOCOMPOSITES WITH HYPER-BRANCHED POLYETHYLENEIMINES BASF SE (DE) 2011-01-27 US disclosed
US-20110009566-A1 THERMOPLASTIC POLYAMIDES HAVING POLYETHER AMINES BASF SE (DE) 2011-01-13 US disclosed
EP-2257597-A2 POLYAMIDE NANOCOMPOSITES WITH HYPER- BRANCHED POLYETHERAMINES BASF SE (DE) 2010-12-08 EP disclosed
EP-2254949-A1 POLYAMIDE NANOCOMPOSITES WITH HYPER-BRANCHED POLYETHYLENIMINES BASF SE (DE) 2010-12-01 EP disclosed
EP-2227507-A2 THERMOPLASTIC POLYAMIDES HAVING POLYETHER AMINES BASF SE (DE) 2010-09-15 EP disclosed
WO-2010028975-A2 THERMALLY CONDUCTIVE POLYAMIDE HAVING INCREASED FLOW CAPABILITY BASF SE (DE) 2010-03-18 WO disclosed
WO-2009115535-A2 POLYAMIDE NANOCOMPOSITES WITH HYPER- BRANCHED POLYETHERAMINES BASF SE (DE) 2009-09-24 WO disclosed
WO-2009115536-A1 POLYAMIDE NANOCOMPOSITES WITH HYPER-BRANCHED POLYETHYLENIMINES BASF SE (DE) 2009-09-24 WO disclosed
WO-2009077492-A2 THERMOPLASTIC POLYAMIDES HAVING POLYETHER AMINES BASF SE (DE) 2009-06-25 WO disclosed
WO-2009050094-A1 THERMOPLASTIC POLYESTER MOLDING COMPOUNDS COMPRISING HIGHLY BRANCHED POLYETHER AMINES BASF SE (DE) 2009-04-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11964949-B2 Substituted phenyloxazolidinones for antimicrobial therapy THPO, TBCD, OXA1L ACKR3 1709/4885HDAC3 170/4885HDAC1 26/4885
US-12600711-B2 Triazacyclododecansulfonamide (TCD)-based protein secretion inhibitors CD274, CD40, ICOS ACKR3 1864/4885HDAC3 4042/4885HDAC1 4537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.